The weight loss drug boom isn’t over yet — here’s what to expect in the year ahead
George Frey | Bloomberg | Getty ImagesWeight loss drugs exploded into the public eye this year, and 2024 will bring ...
Tag: Eli Lilly and Co
Pfizer’s twice-daily weight loss pill joins a long list of obesity drug flops
Sopa Images | Lightrocket | Getty ImagesPfizer's twice-daily version of its experimental weight loss pill has now joined a long ...
Pfizer swings to quarterly loss due to Paxlovid, Covid vaccine write-offs
Pfizer on Tuesday reported a narrower-than-expected adjusted loss for the third quarter as the drugmaker recorded charges largely related to ...
‘Miracle drug’ euphoria: Experts warn widespread use of weight loss medicine faces major hurdles
Two experts see major challenges facing the adoption of new obesity drugs.Dr. Kavita Patel, a physician and NBC News medical ...
Stocks making the biggest moves midday: Novo Nordisk, DaVita, Exxon Mobil, Amgen and more
A box of Ozempic, a semaglutide injection drug used for treating Type 2 diabetes made by Novo Nordisk.George Frey | ...
Stocks making the biggest moves midday: Splunk, Cisco, Broadcom, Fox and more
A sign is posted in front of a Broadcom office in San Jose, California, on June 3, 2021.Justin Sullivan | ...
Ozempic, Wegovy may curb drinking, smoking and other addictive behaviors – here’s what we know
An Ozempic (semaglutide) injection pen is seen on a kitchen table in Riga, Latvia on 06 August, 2023. Jaap Arriens | ...
Wegovy heart health data is promising — but insurers face long road, high cost to cover obesity drugs
A selection of injector pens for the Saxenda weight loss drug are shown in this photo illustration in Chicago, Illinois, ...
Stocks making the biggest moves midday: Beyond Meat, Chegg, PNC Financial, Dish and more
PNC Financial, Citizens Financial, M&T Bank — Regional bank stocks were broadly under pressure on Tuesday after Moody's downgraded the ...
Eli Lilly expects FDA decision on Alzheimer’s treatment donanemab by the end of the year
Eli Lilly on Monday said it applied for full U.S. Food and Drug Administration approval of its Alzheimer's treatment, donanemab, ...
